3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
5
Gastrointestinal
2
Breast
2
Thoracic
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Conditions
Prostatic Neoplasms
4
Urinary Bladder Neoplasms
3
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Emergence Delirium
1
Delirium
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
28
Docetaxel
21
Gemcitabine
19
Nivolumab
14
Paclitaxel
13
Prednisone
11
Leuprolide
11
pazopanib
10
Radiotherapy
10
Cisplatin
10
Sunitinib
9
Sorafenib
9
Ipilimumab
8
Blood Specimen Collection
8
Bevacizumab
8
avelumab
7
Therapeutics
7
Thalidomide
7
Cyclophosphamide
7
Carboplatin
7
atezolizumab
6
Standard of Care
6
Radiation
6
Mitomycin
6
Interleukin-2
6
Cetuximab
6
Axitinib
6
padeliporfin
5
cemiplimab
5
Radiosurgery
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Propofol
×
Genitourinary
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled